Hepatitis C New Drug Research And Liver Health
  • HCV News Of The Day
    • 2013/HCV Drugs News Digest
    • HCV Drugs: News Digest>
      • News Archive
      • Liver HCV : Specialty news digest
  • 2013 - Breaking Conference Reports/Hepatitis C
    • Breaking Conference Reports >
      • EASL 2012 Meeting Summary>
        • EASL Summary Of The 2011 March Meeting
      • AASLD- Nov 2011 Annual Meeting>
        • Conference Archive
  • Blog: New HCV Drug Updates
  • HCV FAQ
  • HCV: Newly Diagnosed?
    • Challenges-issues in managing hepatitis C
    • Ask Me A Question About Hepatitis C
  • What to do with a positive hepatitis C test
  • 2013-HCV Abstract Corner
    • HCV Abstract Corner>
      • Archive; Abstract Corner
  • 2013-Hepatitis C Full Text Articles
    • Hepatitis C Treatment Complete Studies 2012>
      • Potential new method to block the lifecycle of the Hepatitis C virus
      • Hepatitis C Treatment Complete Studies 2011
  • 2013/HCV Multimedia Videos Podcasts
    • Multimedia/Videos-Podcasts>
      • Watch How Hepatitis C Protease Inhibitors Work>
        • Multimedia; Archives Videos and Podcasts
  • 2013 Stem Cell News and Research
    • Liver-2012 Stem Cell Updates
    • Liver: 2011 Stem Cell Updates
    • What Are Stem Cells?>
      • Future applications of human stem cells
  • Recommended; Stem Cell Blogs
  • Understanding Hepatitis C
  • Natural History Of HCV
    • A 20-year cohort study on the natural history of untreated HCV infection
  • Hepatitis C Disease Progression
    • NIH scientists identify likely predictors of hepatitis C severity
    • HCV Epidemiology, Diagnosis and Disease Progression
    • Hepatitis C may increase deaths from both liver-related and other diseases>
      • Mortality in advanced HCV /long-term peginterferon
    • Host Factors on Management of HCV
  • Transmission
    • How Soon To Initiate HCV Therapy After Transmission
    • Does the Hepatitis C virus survive in dried blood ?
    • Viral Load Tied to Vertical Transmission of Hepatitis C
    • Hey Can I Get Hep C From......
    • HCV infections transmitted via a clinical setting
    • What Should I Do If I Get A Needlestick
  • How are the different types of hepatitis transmitted
    • New challenges in viral hepatitis
    • Hepatitis A virus infection in high-risk subjects
  • Your Liver Functions
  • Liver Function Tests
    • HCV-Persistently Normal (ALT) Alanine Aminotransferase Levels
    • Hey, I have a question about hcv tests and my liver
    • ALT used to separate those infected with HCV from those at low risk of liver disease
  • Lab Reports
  • HCV Viral Load Test
  • Liver Biopsy/Noninvasive Tests
    • Is there still a role for liver biopsy in managing hepatitis C virus infections?
    • Overview of Liver Biopsy Procedure
    • Three Algorithms of Non-invasive Markers of Fibrosis in Chronic Hepatitis C
    • FibroScan comparison to liver fibrosis biomarkers
  • Chronic HCV Symptoms
    • Fatigue and HCV
    • Sleep Disturbance in Chronic HCV
    • Skin Rash/Hepatitis C
    • Liver Disease: Bone Loss "It Ain't Like Menopause!"
  • HCV Neuropsychiatric symptoms-“brain fog”
    • HCV-Related Nervous System Disorders
    • Hepatitis C Virus and the Brain
    • Liver-induced inflammation hurts the brain
    • The Brain on Fire: Inflammation and Depression
  • Conditions Outside The Liver
    • Prevalence of fibromyalgia among patients with chronic hepatitis C
    • Lichen Planus and The Hepatitis C Virus
    • Dermatologic Disorders and Liver Disease
  • Chronic hepatitis C: Treat or wait?
    • Preparing For Treatment>
      • Starting Hepatitis C Treatment: Tips and Information 2011
      • Adherence To HCV Treatment-Review
      • Treating Hepatitis C; What can you do to increase your chance for SVR?
  • Hepatitis C advanced fibrosis: Treat or Wait
  • Approved Treatments for Hepatitis C
    • Adults:Treating Hepatitis C
    • Interferons and hepatitis C virus
  • HCV Treatment Failure Can Still Mean Less Liver Inflammation
  • 2013 - Current and Future Therapies for Hepatitis C
    • 2012 Future Prospects-Treatment of HCV>
      • Advances in the treatment of hepatitis C virus infection.
  • Protease inhibitors geno-1:New standard of care
    • Treating HCV Genotype 1 In The Real World
    • 2012 - Direct acting antivirals for the treatment of chronic hepatitis C
    • HCV:End of the Beginning-Possibly-Beginning of the End
    • Patients’ Expectations About New HCV Direct-Acting Antivirals Often Unrealistic
    • What Are NS5A inhibitors ?
    • Hepatitis C Treatment Nonresponders
    • New 2011 AASLD guidelines for treating HCV
    • Treating New and Old Therapies>
      • High-grade liver inflammation may predict treatment response
  • HCV Resistance To New And Experimental Drugs
    • Understanding Resistance in Chronic HCV Infection
  • Boceprevir & Telaprevir
    • FDA Telaprevir/Boceprevir Transcript
    • Pocket Guide Telaprevir/Boceprevir
    • Quick Facts- Direct-acting antivirals Telaprevir/Boceprevir
    • Telaprevir Or Boceprevir: What Is My Chance For A Cure?
  • 2013 News/Incivek (Telaprevir)
    • News/Telaprevir>
      • Telaprevir-IFN/ribavirin Hints at Response
      • Telaprevir FDA Approval>
        • Help-How Do I Take Incivek-telaprevir ?
        • Quick Study Of Telaprevir
        • Cost Of Treating With Telaprevir
  • 2013 News/Victrelis (Boceprevir)
    • News/ Boceprevir>
      • VICTRELIS-Boceprevir: Prescribing-Medication Guide
      • 2011;Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
      • 2011-Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  • Side Effects-Interferon Free Therapies
  • Drug-Drug Interactions In Triple-Therapy
  • 2013/HCV Triple-therapy Side Effects
    • Boceprevir,Telaprevir Less Side Effects?>
      • 2013-HCV therapy geno 1: management of side-effects
      • Dry Mouth and Treatment >
        • Dry Mouth (Xerostomia)
      • Important updates to PegIntron labeling
      • Peginterferon alfa-2a Drug Interactions
      • HCV Treatment: Peginterferon and Ribavirin Side Effects
  • Genotypes/Treatment
    • Treatment Duration in Hepatitis C Virus Genotype 2/3-infected Patients
    • Impact of IL28B on Liver Histopathology in HCV Genotype 2/3
    • Genotype 3/HCV Treatment
    • HCV-Genotype 5 or 6
    • Hepatitis C-Genotype 4>
      • How to optimize HCV therapy in genotype 4 patients
      • Geno 4-Pioglitazone Decreases HCV Viral Load
    • Telaprevir/Boceprevir *genotype 1,2,3
    • (HCV) genotypes in the severity of liver disease
  • What Is The IL28B gene ?
    • Hepatitis C Test:Likelihood of achieving SVR>
      • IL28B and HCV immune responses
  • Index-Current Hepatitis C Drugs In Development
  • 2013-Interferon Free Combinations
    • Interferon-free combinations
    • 2013-Interferon free therapy w-direct acting antivirals for HCV
  • 2013 Sofosbuvir (GS-7977)
    • GS-7977-Formally PSI-7977 >
      • PSI-7977 peg/riba Geno 2/3 PROTON Trial
  • Sofosbuvir(GS7977)/Simeprevir(TMC435)
    • Interferon-Free Combo PSI-7977-TMC435
  • Sofosbuvir (GS-7977)/Ledipasvir (GS-5885)
  • GS-5885, an NS5A Inhibitor
  • ABT-450/r, ABT-267, ABT-333
  • Faldaprevir (BI 201335) and BI 207127 Interferon-Free
    • NS3/4A protease inhibitor BI201335
  • Miravirsen First MicroRNA-Targeted Drug
  • BMS-790052 (Daclatasvir)
  • Daclatasvir/VX135
  • ALS-2200 (VX-135)
  • BMS-790052/BMS-650032 Interferon-sparing
  • (TMC435) Simeprevir
  • TMC435 monotherapy in HCV genotypes 2-6
  • Simeprevir (TMC435) and TMC647055
  • Simeprevir,TMC647055 and IDX719
  • TMC435-daclatasvir-BMS-790052
  • Danoprevir-RG7227 direct-acting antiviral
  • Mericitabine- Polymerase Nuc
  • Sovaprevir (Formerly ACH-1625)
  • ACH-3102 NS5A inhibitor
  • INCIVEK, VX-222/Ribavirin
  • MK-5172 protease inhibitor
  • HCV/New Drug Pipeline
  • 2013/Hepatitis C Clinical Trials
    • Clinical Trials>
      • Learning About Clinical Trials
      • Boceprevir and Telaprevir Trials>
        • Telaprevir REALIZE STUDY
  • HCV Trials/Discontinued Or On Hold
    • Idenix IDX184-Hepatitis C drug
    • TMC435-BMS-986094-formerly INX-189
  • Women's Health; Treating Hepatitis C
    • Early Menopause and Response to HCV Treatment
  • Hepatitis C in Pregnancy
  • Treating Hepatitis C In Children
    • 2012 Hepatitis C infection in children
    • Autoimmunity/Extrahepatic Manifestations in HCV Treatment-Naïve Children
    • Study-long-term safety/durability of virologic response in paediatric patients who were previously treated w-interferon alfa-2b plus ribavirin for 48 weeks
  • Liver Disease in Elderly Patients
  • Dental considerations in patients with liver disease
    • HCV: Dental management-Diagnosis of extrahepatic manifestations>
      • Dental problems delaying the initiation of interferon
  • Fibrosis
    • Is there a natural way to improve liver fibrosis ?
  • 2013 News/Fibrosis
    • News: Fibrosis
  • Cirrhosis
    • What Is Cirrhosis ?
    • Advanced Liver Disease: What Every HCV Treater Should Know
    • The Patient With Cirrhosis: Don't Miss This
    • Hey, I have a question about cirrhosis
    • Physical Findings Suggestive Of Cirrhosis/Photos
    • Staging Cirrhosis>
      • When the Spleen Gets Tough, the Varices Get Going
    • Management Cirrhosis: How Are We Doing?
    • Cirrhosis Regression
    • Cirrhosis ; Surgery in the Patient with Liver Disease
    • Hepatic Encephalopathy>
      • Varices
      • Ascites
      • Management of ascites
  • 2013 News/Cirrhosis
    • News: Cirrhosis>
      • GI Bleeds: Withholding Transfusions Boosts Survival
  • Liver Transplant
    • New HCV Drugs:Expected Risks-Challenges in Liver Transplant
    • Prevention of hepatitis C recurrence after liver transplantation>
      • Effects of Telaprevir on Cyclosporine and Tacrolimus Pharmacokinetics Make Utility in Post-OLT Setting Uncertain
      • HCV Treatment After Liver Transplant
      • Antivirals Ineffective Against HCV After LT
  • 2013 News/Transplant
    • Liver Transplant News
  • Hepatocellular Carcinoma
    • Audio:Liver Cancer
    • Radioembolisation (RE),Selective Internal Radiation Therapy (SIRT)
    • Diagnosis (markers) of early hepatocellular carcinoma
    • Intrahepatic cholangiocarcinoma
    • Treatment TheraSphere/HCC/primary liver cancer
    • Liver Cancer : Microwave Ablation (MWA)
    • Pain May Predict Liver Cancer Prognosis
    • What Is the Indication for Sorafenib in Hepatocellular Carcinoma?
    • Liver Cysts and Tumors"Two Totally Different Concepts"
    • Interactive map of cancer mortality risk worldwide
  • 2013 News/Liver Cancer
    • Liver Cancer News and Updates
    • Vitamin E may lower liver cancer risk
  • Guidelines Nonalcoholic Fatty Liver Disease (NAFLD)
    • Fatty Liver And HCV>
      • Touching some firm ground in the epidemiology of NASH
      • Ultrasound/Liver Biopsy
      • Fatty Liver and Treatment
      • Liver fibrosis/Fatty Liver
  • 2013-Coffee and Liver Disease
  • Liver Regeneration
  • Liver Health
    • Choline: Great for the Liver
    • Medications for sleep in liver disease
    • The odds of gallbladder disease in Hepatitis C Patients
    • HCV & Gallbladder Disease:
    • Enlarged Spleen
    • HCV And Cardiovascular Risk
  • Nutrition-Herbs-Vitamins
    • Vitamin D and Treatment
    • Liver Disease - The Mediterranean Diet
    • Diet: Cirrhosis>
      • Low-Salt Diet-A Must in Cirrhosis
      • Diet for Liver Disease Low Sodium and More
      • Vitamin B12 supplements may help treat hepatitis
      • Nutrition in end-stage liver disease
      • Cirrhosis; Vitamin K Deficiencies
      • Vitamin D Levels In Cirrhosis
      • Vitamin D could de-stress Liver Disease Treatments
      • Drugs And Cirrhosis
      • Cancer and Berries
  • 2013-Silymarin for HCV infection
  • Milk Thistle
    • 2012-Milk Thistle No Help in Tough Hepatitis C Cases
    • Silymarin-Milk Thistle for NAFLD
    • Milk thistle"- Silibinin in hepatitis C related liver transplantation
    • Milk Thistle is coming to America
    • Caution! Herbs and Nutritional Supplements
  • HCV Drugs: Financial Support
  • HCV Filing For Social Security
  • Hepatitis C: A Rational Call To Arms
    • Hepatitis C; A Forced Legacy
    • Outsourcing:Globalization of the pharmaceutical industry>
      • Inspirational
  • Hepatitis C Links / Best On The Web
    • Chat and Message Boards
  • Whose Website Is This ?
  • Feedback/Contact Us
Hepatitis C Cardiovascular Risk

 

Picture

Hep C influences atherosclerosis and cardiometabolic risk factors k .k

Hepatitis C infection and clearance influences atherosclerosis and cardiometabolic risk factors, finds the latest issue of Gut.
Chronic hepatitis C (HCV) infection is associated with diabetes and favorable lipids.
Dr Aya Mostafa and colleagues from Egypt studied the effect of this paradox on atherosclerosis and cardiometabolic response to Hepatitis C clearance. ,
The research team identified 329 chronically infected patients.
There were 173 with cleared infection and 795 never infected participants aged 35 years or over attended for baseline investigations. m
A subsample of 192, 115 and 187, respectively, underwent ultrasound.
n
The team's main outcome measures included diabetes, fasting glucose, lipids and fat deposition on ultrasound. ,
Carotid intima-media thickness measured atherosclerosis.
Diabetes prevalence was raised in those never infected.
Mesenteric fat was raised in chronic, and cleared infection vs never infected.
The team observed that LDL cholesterol was lower in chronic, but similar in cleared versus never infected.
The researchers found that carotid intima-media thickness did not differ by infection status.
Adjustment for cardiovascular risk factors increased intima-media thickness in chronic infection versus never infected individuals. ,

Dr Mostafa's team commented, "Hepatic function normalization with Hepatitis C clearance may account for reversal of favorable lipids observed with Hepatitis C infection."
"Hyperglycemia and visceral adiposity appear less amenable to Hepatitis C resolution."
"These different cardiovascular risk patterns may determine equivalent atherosclerosis risk by infection status." ,
"However, once these factors were accounted for, those with chronic infection had raised intima-media thickness, suggesting a direct effect of infection."

, Gut 2010: 59: 1135-1140

30 July 2010

Also See
 http://www.hivandhepatitis.com/hep_c/news/2010/0730_2010_a.html


Copyright 2010-2013 Hepatitis C New Drug Research And Liver Health